[Carcinoembryonic antigens (CEA) in patients with metastatic breast cancer under endocrine and therapeutic treatment (author's transl)].
Carcinoembryonic antigen (CEA) was determined in 72 patients with metastatic breast cancer under various kinds of treatment. In 53 cases, CEA levels were elevated. They correlated with free interval, metastatic spreading, alkaline phosphatase (AP) and gamma-glutamyltranspeptidase (gamma-GT). Serial CEA determinations in 50 of the 72 patients revealed increased CEA levels in connexion with progressive tumour growth and decreased CEA levels in connexion with response to treatment. CEA may therefore be useful in helping to assess the extension of the tumour and the effect of treatment in patients with matastatic breast cancer.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology*; D002272:Carcinoembryonic Antigen / Q000032:analysis*; D002369:Castration; D013196:Dihydrotestosterone / Q000627:therapeutic use; D004997:Ethinyl Estradiol / Q000627:therapeutic use; D005260:Female; D006801:Humans; D009362:Neoplasm Metastasis; D011374:Progesterone / Q000627:therapeutic use; D012075:Remission, Spontaneous; D013629:Tamoxifen / Q000627:therapeutic use
D000970:Antineoplastic Agents; D002272:Carcinoembryonic Antigen; D013196:Dihydrotestosterone; D013629:Tamoxifen; D004997:Ethinyl Estradiol; D011374:Progesterone
Carcinoembryonales Antigen (CEA) im Plasma bei Patienten mit metastasierenderm Mammakarzinom unter endokriner und zytostatischer Therapie.